Manipal Health IPO Opens: ₹9,275 Crore Issue, GMP, Allotment and Listing Details

Manipal Health IPO opened for public subscription on Wednesday, July 29, 2026, with Manipal Health Enterprises Ltd seeking to raise around ₹9,275 crore through its maiden public offering. The Bengaluru-based hospital chain, backed by Temasek and Ranjan Pai, has launched one of the largest healthcare IPOs in the Indian primary market. The three-day issue will remain open until July 31.

Manipal Health IPO had already received a strong response from institutional investors before opening for the public. The company raised ₹4,167 crore from anchor investors on July 28, ahead of the IPO launch. The anchor book attracted several prominent global investors as well as leading domestic mutual funds.

Manipal Health IPO Anchor Investors Raise ₹4,167 Crore

Manipal Health IPO anchor investors invested ₹4,167 crore ahead of the public issue. According to a circular uploaded on the BSE and cited by PTI, the company allotted more than 7.06 crore equity shares to anchor investors at ₹590 per share, which is the upper end of the IPO price band.

Manipal Health anchor book included Abu Dhabi Investment Authority (ADIA), Allianz Global Investors Fund, Morgan Stanley Asia, Natixis International Fund, Societe Generale and Goldman Sachs Bank Europe. Domestic investors participating in the anchor round included ICICI Prudential Mutual Fund, Kotak Mutual Fund, Aditya Birla Sun Life Mutual Fund, UTI Mutual Fund and HSBC Mutual Fund.

Manipal Health IPO Price Band and Issue Size

Manipal Health IPO price band has been fixed at ₹560 to ₹590 per equity share. At the upper end of the price band, the issue is valued at around ₹9,275 crore, while the issue size at the lower end is estimated at approximately ₹9,210 crore.

Manipal Health IPO issue size consists of a fresh issue of equity shares worth up to ₹8,000 crore and an offer for sale (OFS) of up to 2.16 crore equity shares by existing shareholders. The fresh issue will bring new funds into the company, while proceeds from the OFS will go to the shareholders selling their stakes.

Manipal Health IPO OFS Details

Manipal Health IPO OFS includes stake sales by several existing shareholders. Promoters Imperius Healthcare Investments Pte. Ltd. and Manipal Education and Medical Group India Pvt. Ltd. will pare their holdings through the offer for sale.

Manipal Health existing shareholders participating in the OFS also include TPG SG Magazine Pte. Ltd., Seventy Second Investment Company LLC, Ammar Sdn Bhd, Novo Holdings Invest Asia and Phoenix Bear Investments, LLC.

Manipal Health IPO Use of Proceeds

Manipal Health IPO proceeds will be used largely for debt reduction and strategic requirements. The company plans to utilise ₹5,378 crore from the fresh issue towards repayment or prepayment of borrowings of its subsidiary, Manipal Hospitals Pvt. Ltd.

Manipal Health debt repayment is expected to help strengthen the company’s balance sheet and potentially reduce its interest burden. The company has also earmarked ₹574 crore for acquiring the minority stake in its step-down subsidiary Sahyadri Hospitals Pvt. Ltd.

Manipal Health IPO funds remaining after the proposed debt repayment and acquisition will be used for general corporate purposes. The allocation of a substantial portion of the fresh issue towards debt reduction is one of the key aspects investors may consider while evaluating the offer.

Manipal Health IPO Lot Size and Minimum Investment

Manipal Health IPO lot size has been fixed at 25 equity shares. At the upper end of the price band of ₹590, retail investors will need a minimum investment of ₹14,750 for one lot. Investors can bid for 25 shares and in multiples thereof.

Manipal Health IPO reservation provides for up to 75% of the offer for qualified institutional buyers (QIBs), 15% for non-institutional investors (NIIs) and 10% for retail investors. Equity shares worth up to ₹15 crore have also been reserved for eligible employees. Employees will receive a discount of ₹56 per share.

Manipal Health IPO GMP Today

Manipal Health IPO GMP was reported at around ₹8, according to the latest grey market trends cited by Economic Times. Based on the upper IPO price of ₹590 and a GMP of ₹8, the implied estimated listing price stands at around ₹598, indicating a premium of approximately 2% over the upper price-band level.

Manipal Health IPO grey market premium suggests only a modest potential listing gain if the trend continues. However, grey market premium is unofficial and unregulated and should not be considered a reliable indicator of the actual listing price or future performance of the shares.

Manipal Health IPO GMP can change before listing depending on market sentiment, demand and broader market conditions. Investors should therefore avoid relying solely on the grey market premium while deciding whether to subscribe to the issue.

Manipal Health IPO Allotment and Listing Date

Manipal Health IPO allotment is expected to be finalised on August 3, according to the issue timeline cited by Economic Times. After the allotment process, shares are expected to be credited to successful applicants before the proposed listing.

Manipal Health IPO listing date is expected to be August 5 on both the NSE and BSE. The proposed listing date remains subject to completion of the issue process and applicable exchange procedures.

Manipal Health Enterprises Business Overview

Manipal Health Enterprises operates a pan-India network of multispecialty hospitals and provides healthcare services ranging from outpatient care to tertiary and quaternary interventions. The company is part of the Manipal Group founded by T.M.A. Pai and has built a significant presence in India’s healthcare sector.

Manipal Health hospital network provides treatment across a range of specialties, including oncology, cardiology, neurology, orthopaedics, organ transplants and preventive healthcare. The company has expanded its network through acquisitions, investments in medical infrastructure and digital healthcare initiatives.

Manipal Health hospitals stood at 38 as of September 30, 2025, with 10,761 licensed beds. On a pro forma basis, the network consisted of 48 hospitals with 12,367 licensed beds across 14 states and Union Territories.

Manipal Health expansion continued in November 2025 when the company commenced operations at its 49th hospital in Bengaluru. Its licensed bed capacity subsequently reached 12,631 as of December 31, 2025.

Manipal Health latest network figures cited by Economic Times state that as of March 31, 2026, the company operated 49 hospitals with 13,037 licensed beds and 21 clinics across India. The company employed 24,240 full-time staff, including 11,048 nurses, 6,362 paramedics and 6,830 administrative personnel.

Manipal Health Financial Performance

Manipal Health financial performance remained strong in the six months ended September 30, 2025. The company reported revenue from operations of ₹4,713 crore and net profit of ₹571.8 crore during the period.

Manipal Health revenue and profit are among the key financial parameters investors may consider while evaluating the IPO. The company’s scale, hospital network and expansion strategy have positioned it as a major player in India’s growing multispecialty healthcare market.

Manipal Health growth strategy includes acquisitions, capacity expansion, investments in medical infrastructure and digital healthcare initiatives. The company is also targeting further bed additions, with SBI Securities highlighting plans to add more than 2,400 beds by FY30.

Manipal Health IPO Valuation

Manipal Health IPO valuation is one of the key factors investors are considering before subscribing to the issue. The IPO is being launched at a price band of ₹560 to ₹590 per share, with the company valued at more than ₹77,600 crore at the upper end of the price band.

Manipal Health valuation has been viewed differently by brokerages. While several analysts have highlighted the company’s strong market position, revenue growth, acquisition track record and expansion potential, some have cautioned that the premium valuation could limit near-term upside.

Should You Subscribe to Manipal Health IPO?

Manipal Health IPO subscription has received broadly positive views from several brokerages, although analysts have also pointed to valuation concerns. SBI Securities has reportedly given a ‘Subscribe’ rating, citing the company’s leadership in the multispecialty hospital segment, strong acquisition track record, planned addition of more than 2,400 beds by FY30 and potential for margin expansion.

Manipal Health IPO analyst views also point to potential benefits from debt reduction and the integration of Sahyadri Hospitals. SBI Securities expects the company’s financial profile to benefit from lower debt and possible margin improvement as the business continues to expand.

Manipal Health IPO recommendation from Anand Rathi Research is also ‘Subscribe for Long Term’. However, the brokerage noted that the IPO is valued at around 85.4 times FY26 earnings, highlighting the premium investors are being asked to pay for the company’s growth prospects.

Manipal Health IPO neutral views have also emerged. Arihant Capital and Angel One have maintained a ‘Neutral’ stance, arguing that the company’s strong fundamentals and long-term growth prospects are already reflected in the IPO valuation.

Manipal Health IPO valuation concerns have also been highlighted by Axis Capital, Sushil Finance and Ashika Research. These research houses have pointed to healthy revenue and earnings growth, operational efficiencies and the company’s strong market position, while cautioning that the rich valuation could restrict near-term upside.

Manipal Health IPO Verdict

Manipal Health IPO verdict depends largely on an investor’s time horizon and risk appetite. The company enters the market with a strong healthcare franchise, a significant presence in key metros and a growth strategy driven by acquisitions and capacity expansion.

Manipal Health long-term prospects could benefit from India’s growing demand for organised healthcare services. The company’s hospital network, expansion plans, acquisition strategy and investments in medical infrastructure provide several potential growth drivers.

Manipal Health IPO debt reduction is another important positive factor. The planned use of ₹5,378 crore to repay or prepay borrowings could materially reduce debt and potentially lower interest costs. The proposed ₹574 crore investment in acquiring a minority stake in Sahyadri Hospitals could also support the company’s expansion strategy.

Manipal Health IPO listing gains, however, may be limited if the reported GMP trend remains around ₹8. The implied premium of approximately 2% over the upper issue price suggests relatively modest listing-day upside. Investors looking specifically for quick listing gains may therefore need to be cautious about the current valuation and grey market trend.

Manipal Health IPO investment outlook appears more relevant for investors seeking long-term exposure to India’s healthcare growth story than for investors focused only on listing-day gains. The company’s strong market position and expansion plans provide a long-term investment case, but the premium valuation remains an important risk factor.

Investors should carefully review the company’s offer documents, financial performance, valuation, business risks and future growth plans before making an investment decision. Grey market premium is unofficial and should not be treated as a guarantee of listing performance.

Manipal Health IPO Key Details at a Glance

Manipal Health IPO Lead Managers and Registrar

Manipal Health IPO book-running lead managers include Axis Capital, Kotak Mahindra Capital Company, Goldman Sachs (India) Securities, Jefferies India, J.P. Morgan India, UBS Securities India and DBS Bank India. KFin Technologies has been appointed as the registrar to the issue.

Manipal Health IPO listing is proposed on both the BSE and NSE. Investors can track the final allotment and listing-related updates through the relevant exchange and registrar announcements.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investments in IPOs and securities are subject to market risks. Investors should read the official offer documents carefully and consult a qualified financial adviser before making investment decisions.

Source: PTI and Economic Times reports cited in the supplied reference material.